Blood tests with enzyme profiling diagnose pancreatic cancer in Stage I and Stage II * The method adds efficiency to cancer detection while delivering better performance than //prevailing biomarkers * ...

The incidence of pancreatic adenocarcinoma increases across all age groups, whereas colorectal adenocarcinoma increases only among younger age groups.

This discovery opens the door for new kinds of treatments. If doctors could develop drugs that block CD9 or stop cancer cells ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...

A metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) could be used to address this type of cancer that often resists treatments. Scientists at the University of Michigan have ...

Arvind Trindade, MD, discusses the background of a study investigating rates of pancreatic and colon cancer among younger patients.

From 2000 to 2021, there was an increase in the incidence of pancreatic adenocarcinoma, which was seen in all age groups.

From 2000 to 2021, there was an increase in the incidence of pancreatic adenocarcinoma, which was seen in all age groups, ...

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ's dense tissue to define the margins between malignant and normal tissue. A new study uses DNA origami ...

In the US, the incidence of pancreatic cancer is increasing in patients of all ages, and the incidence of colorectal cancer is increasing in patients aged 15-34 years.

Novocure (NVCR) announced that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for ...